ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OSIP Osi Pharmaceuticals Inc. (MM)

57.49
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Osi Pharmaceuticals Inc. (MM) NASDAQ:OSIP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 57.49 0 01:00:00

- Amended Statement of Ownership: Solicitation (SC 14D9/A)

22/04/2010 10:05pm

Edgar (US Regulatory)





 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________

SCHEDULE 14D-9


Solicitation/Recommendation Statement under Section 14(d)(4)
of the Securities Exchange Act of 1934
(Amendment No. 4)

OSI Pharmaceuticals, Inc.
(Name of Subject Company)

OSI Pharmaceuticals, Inc.
 (Name of Person Filing Statement)

Common Stock, $0.01 par value per share
(Title of Class of Securities)

671040103
(CUSIP Number of Class of Securities)

Barbara A. Wood, Esq.
Senior Vice President, General Counsel and Secretary
41 Pinelawn Road
Melville, New York 11747
 (631) 962-2000

(Name, address and telephone number of person authorized to receive notices
and communications on behalf of the persons filing statement)

With copies to:

Roger S. Aaron, Esq.
Robert B. Pincus, Esq.
Steven J. Daniels, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, New York 10036
(212) 735-3000

□      Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
 
 


 
 
 

 

This Amendment No. 4 ("Amendment No. 4") amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of OSI Pharmaceuticals, Inc., a Delaware corporation (“OSI”), filed with the Securities and Exchange Commission on March 15, 2010, as amended (as so amended, the “Schedule 14D-9”).  Except as set forth in this Amendment No. 4, the information set forth in the Schedule 14D-9 remains unchanged.


Item 9.  Exhibits.

Item 9 to the Schedule 14D-9 is hereby amended and supplemented by adding the following exhibits:

Exhibit No.
Document
   
(a)(13)
Press release dated April 22, 2010, filed as Exhibit 99.1 to OSI’s Current Report on Form 8-K filed on April 22, 2010 (file no. 000-15190) and incorporated herein by reference.
   
(a)(14)
Script for OSI’s First Quarter 2010 Earnings Conference Call held on April 22, 2010, filed as Exhibit 99.2 to OSI’s Current Report on Form 8-K filed on April 22, 2010 (file no. 000-15190) and incorporated herein by reference.

 
 

 

 
SIGNATURE
 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 

 
OSI PHARMACEUTICALS, INC.
   
   
 
By:
/s/ Barbara A. Wood
 
   
Barbara A. Wood
 
   
Senior Vice President, General
   
Counsel and Secretary
 
Dated:  April 22, 2010
 


1 Year Osi Pharmaceuticals Chart

1 Year Osi Pharmaceuticals Chart

1 Month Osi Pharmaceuticals Chart

1 Month Osi Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock